The North America human leukocyte antigen (HLA) testing market is expected to grow from US$ 324.49 million in 2022 to US$ 504.72 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.
Human leukocyte antigens (HLAs) are specialized proteins present on all cell surfaces of the human body except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues. The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice area. Governments of various countries are taking initiatives to spread awareness about the need for organ donation and the benefits of organ transplantation in certain treatment procedures. For instance, the Organ Procurement and Transplantation Network (OPTN) has implemented a few strategies to improve the number of organ transplantation procedures in the US. These strategies focus on increasing the number of organ and tissue transplants among patients with end-stage organ disease, altering the current organ distribution, and modifying the organ transplantation waitlist by redistributing the existing organ soppy. Furthermore, the OPTN has used out-of-box strategies to improve organ transplantation. These innovative strategies include the optimized use of organs obtained from deceased patients [e.g., donation after cardiac death (DCD) or brain-dead donors], reducing discards of organs, promoting living donation, and improving the rate of potential organ donation authorization. Thus, the growing demand for organ transplantation leads to the requirement of a more substantial number of HLA testing kits and consumables, which drives the HLA testing market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the north america human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.
The North America human leukocyte antigen (HLA) testing market is segmented into product & services, technology, end user, and country. Based on product & services, the market is segmented into reagents & consumables, instruments, and software & services. In terms of technology, the North America human leukocyte antigen (HLA) testing market is divided into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment is sub segmented into PCR-based molecular assays, sequencing-based molecular assays, and others. Based on end user, the market is divided into independent reference laboratories, hospital and transplant centers, and others. Based on country, the North America human leukocyte antigen (HLA) testing market is segmented into the US, Mexico, and Canada.
THERMO FISHER SCIENTIFIC INC.; CareDx; QIAGEN; Illumina, Inc.; Bio-Rad Laboratories, Inc.; TBG Diagnostics Limited; F. HOFFMANN-LA ROCHE LTD.; Takara Bio Inc.; Luminex Corporation; Omixon Inc.; The Sequencing Center; HistoGenetics LLC; CD Genomics; Quintara Biosciences; and CREATIVE BIOLABS, INC. are among the major companies operating in the North America human leukocyte antigen (HLA) testing market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 324.49 Million |
| Market Size by 2028 | US$ 504.72 Million |
| CAGR (2022 - 2028) | 7.6% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product and service
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Human Leukocyte Antigen (HLA) Testing Market is valued at US$ 324.49 Million in 2022, it is projected to reach US$ 504.72 Million by 2028.
As per our report North America Human Leukocyte Antigen (HLA) Testing Market, the market size is valued at US$ 324.49 Million in 2022, projecting it to reach US$ 504.72 Million by 2028. This translates to a CAGR of approximately 7.6% during the forecast period.
The North America Human Leukocyte Antigen (HLA) Testing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Human Leukocyte Antigen (HLA) Testing Market report:
The North America Human Leukocyte Antigen (HLA) Testing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Human Leukocyte Antigen (HLA) Testing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Human Leukocyte Antigen (HLA) Testing Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Human Leukocyte Antigen (HLA) Testing Market
